Bio Nano Consulting (BNC) has signed a collaborative agreement with a top five pharma company to develop assay systems for product discovery and development.
The agreement follows the completion in mid December of a second contract with Targanta Therapeutics, in which BNC used cantilever-array assay system technology to analyse the mechanism of action of Targanta's lipoglycopeptide antibiotic, oritavancin.
'Nanotechnology is finding more and more applications in industry, and BNC is developing a reputation within the pharmaceutical, biotech, medtech and health care industries for providing approaches in research and development,' said Dr David Sarphie, chief executive officer, Bio Nano Consulting.
